Kennedy Jr. Urges FDA to Revise Abortion Pill Label, Vows Comprehensive Health Review

Share this article on your social media platforms: , , or print it for reference .

function setShareLinks() {
var pageUrl = encodeURIComponent(document.location.href);
var tweetText = encodeURIComponent(document.title);
document.getElementById(‘facebookShare’).setAttribute(‘href’, `https://www.facebook.com/share.php?u=${pageUrl}`);
document.getElementById(‘twitterShare’).setAttribute(‘href’, `https://twitter.com/intent/tweet?url=${pageUrl}&text=${tweetText}`);
}
window.onload = function() {
setShareLinks();
};

Health and Human Services Secretary Robert F. Kennedy Jr. has suggested that the Food and Drug Administration (FDA) should change the label on abortion drug mifepristone and conduct a comprehensive review. This statement is following a study revealing higher serious side effects from the pill than previously reported.

Senator Josh Hawley (R., Mo.) questioned Kennedy about mifepristone and cited a conservative Ethics and Public Policy Center study finding serious adverse effects from the abortion drug in almost 11 percent of women.

Jim O’Neill, appointed by President Donald Trump to be HHS Deputy Secretary, made similar comments last week, promising an updated safety review of mifepristone following the same study.

Kennedy, who had previously been a pro-abortion Democrat, has mostly deferred to Trump’s stance on abortion. Robert Kennedy Jr. and Marty Makary, director of the FDA, both faced rigorous examination from both political parties on the topic of mifepristone access.

Senator Hawley, a pro-life advocate, recently introduced legislation to reinstate regulatory safeguards regarding mifepristone.

The EPPC study, based on insurance claims data from 2017 to 2023, concluded that nearly 11 percent of women experience a serious adverse event after a mifepristone abortion. This rate is considerably higher than that stated on the drug’s current label.

The Guttmacher Institute released data in 2024 showing chemical abortions accounted for 63 percent of all abortions in 2023, showing a major increase over the past few years.

Despite Trump’s previous promise that the FDA would maintain access to the abortion pill, his positioning on the issue has been a point of contention for pro-lifers.

A 2024 Supreme Court ruling dismissed a case challenging FDA’s approval on mifepristone citing lack of standing to sue, a disappointment for pro-life advocates.

This information was originally published in an article by the National Review.